Findings

What do systematic reviews say?

5 questions · 5 findings · 2 reviews · Cystic Fibrosis and Genetic Disorders

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 3 · 60%Low 1 · 20%Moderate 1 · 20%High 0 · 0%

Summary of findings ‐ 400 mg inhaled mannitol vs 50 mg inhaled mannitol

Adverse events relating to treatment Scale: mild, moderate, severe and total · adults, children and young people with CF

1 finding from 1 review

Inhaled mannitol for cystic fibrosis 2020 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 600 participants
Moderate

Summary of findings ‐ Inhaled mannitol vs control (non‐respirable mannitol)

Adverse events relating to treatment Scale: mild, moderate, severe and total · adults, children and young people with CF

1 finding from 1 review

Inhaled mannitol for cystic fibrosis 2020 · Cochrane Headline outcomes only
no estimate extracted
123 participants
Low

Summary of findings ‐ Inhaled mannitol vs dornase alfa

Adverse events relating to treatment Scale: mild, moderate, severe and total · children and young adults with CF

1 finding from 1 review

Inhaled mannitol for cystic fibrosis 2020 · Cochrane Headline outcomes only
no estimate extracted
231 participants
Very low

Summary of findings ‐ Inhaled mannitol plus dornase alfa vs dornase alfa

Adverse events relating to treatment Scale: mild, moderate, severe and total · children and young adults with CF

1 finding from 1 review

Inhaled mannitol for cystic fibrosis 2020 · Cochrane Headline outcomes only
no estimate extracted
231 participants
Very low

Summary of findings: Inhaled antibiotics plus IV antibiotics vs IV antibiotics

Adverse events (moderate) · adults and children with cystic fibrosis (during acute exacerbations of lung disease)

It is very uncertain whether summary of findings: Inhaled antibiotics plus IV antibiotics changes adverse events moderate adverse events experienced during and after… compared with IV antibiotics only (very low certainty).

1 finding from 1 review

Inhaled antibiotics for pulmonary exacerbations in cystic fibrosis 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 28 participants
Very low